1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
Pauly, F. LU ; Fjordén, K. LU ; Leppä, S. ; Holte, H. ; Björkholm, M. ; Fluge ; Møller Pedersen, L. ; Eriksson, M. LU
; Isinger-Ekstrand, A.
LU
and Borrebaeck, C. A.K.
LU
, et al.
(2016)
In Blood Cancer Journal
6(11).
p.501-501
- Contribution to journal › Article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
- Contribution to journal › Article
- 2008
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
(2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142
- Contribution to journal › Published meeting abstract
- 2004
-
Mark
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
- Contribution to journal › Article